Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor ( SIR9900 ) in Healthy Adults and Elderly Participants
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70151 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Ofer Michael Gonen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nucleus Network Pty Ltd, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Brain, Protein Kinase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Receptor‐interacting serine/threonine kinase 1 (RIPK1) regulates inflammatory signaling and induces apoptosis and necroptosis. Pharmacological inhibition of RIPK1 kinase activity has demonstrated efficacy in animal models of neurodegenerative, autoimmune and inflammatory diseases. SIR9900 is a potent and selective novel small molecule RIPK1 inhibitor. This first‐in‐human, phase I, randomized, double‐blind, placebo‐controlled study evaluated the safety, pharmacokinetics, and pharmacodynamics of single (3–200 mg) and multiple (3–60 mg daily for 10 days) ascending oral doses of SIR9900 in healthy adult (18–64 years, n = 80) and elderly participants (≥ 65 years, multiple doses 30 mg, n = 8). The study included a food effect component. Overall, SIR9900 was safe and well tolerated with no concerning dose‐dependent trends in safety observed. SIR9900 was rapidly absorbed with a plasma maximum concentration time ( T max ) of 3.0–4.0 h and plasma half‐life ( t 1/2 ) of 31.92–37.75 h following single doses. Similar T max and t 1/2 results were observed following multiple doses. Systemic exposure to SIR9900 increased in a dose‐proportional manner and was similar between adult and elderly participants. No appreciable food effect was observed. The cerebrospinal fluid to unbound plasma ratio was 1.15. A robust pharmacodynamic effect was demonstrated with approximately 90% peripheral target engagement at 3 h post‐dose, and sustained RIPK1 inhibition over the 10‐day treatment period. The promising safety, pharmacokinetic, and pharmacodynamic profile of SIR9900 with central nervous system penetrating potential in healthy adult and elderly participants supports its further clinical development in patients with inflammatory and degenerative diseases, particularly in the central nervous system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nucleus Network Pty Ltd, Melbourne, Victoria, Australia.
- Avance Clinical Pty Ltd, Adelaide, South Australia, Australia.
- Sironax Aus Pty Ltd (a Subsidiary of Sironax Ltd), Sydney, New South Wales, Australia.
ORCID-Profile: Ofer Michael Gonen, Tim Porter, Buwei Wang, Fenchao Xue, Yongfen Ma, Linan Song, Pei Sun, Weiliang Fan, Yang Shen
Zitieren
APA
Gonen, O. M., Porter, T., Wang, B., Xue, F., Ma, Y., Song, L., Sun, P., Fan, W., & Shen, Y. (2025). Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor ( SIR9900 ) in Healthy Adults and Elderly Participants. Clinical and Translational Science. https://doi.org/10.1111/cts.70151
Vancouver
Gonen OM, Porter T, Wang B, Xue F, Ma Y, Song L, et al. Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor ( SIR9900 ) in Healthy Adults and Elderly Participants. Clinical and Translational Science. 2025. doi:10.1111/cts.70151
BibTeX
@article{Gonen2025,
author = {Gonen, Ofer Michael and Porter, Tim and Wang, Buwei and Xue, Fenchao and Ma, Yongfen and Song, Linan and Sun, Pei and Fan, Weiliang and Shen, Yang},
title = {Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor ( SIR9900 ) in Healthy Adults and Elderly Participants},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70151}
}
EUVIMED